TrakCel and Ori Biotech sign a collaboration agreement for supply chain orchestration within cell and gene therapy manufacturing
Cardiff and London UK, February 25, 2020 - TrakCel, a leading software developer for cell and gene therapy supply chain tracking and orchestration systems, and Ori Biotech Ltd, (Ori), an innovator in cell and gene therapy (CGT) manufacturing, announce today a non-exclusive strategic partnership to achieve supply chain orchestration within closed system manufacturing for the cell and gene therapy sector.
The Ori platform enables therapy developers and contract manufacturers to achieve automated CGT manufacturing in a closed platform. The collaboration will enable users of the Ori Biotech manufacturing platform to benefit from live supply chain visibility through TrakCel software and TrakCel customers to have greater visibility into the manufacturing process via data services within the Ori platform. Resulting from the agreement, TrakCel and Ori will develop suitable points of integration in order for a shared data platform to be available to partners.
“TrakCel has developed an extensive partnership network with contract manufacturers and companies across the cell and gene therapy sector. This enables therapeutic developers to be supported by more standardized and integrated solutions,” said Fiona Withey, Co-Founder and CEO, TrakCel. “Closed system manufacturing is becoming progressively more important for the ongoing future of the cell and gene therapy sector, and we look forward to working with Ori to offer more integrated solutions to the wider industry.”
“Ori Biotech is continuing to build a network of best-in-class partners across the cell and gene therapy ecosystem to help enable our provision of integrated, closed system manufacturing to the cell and gene therapy industry,” said Farlan Veraitch, Co-Founder and CSO, Ori Biotech. “The integration of TrakCel’s advanced therapy supply chain tracking software with the Ori full-stack platform is another step forward enabling our customers to have full visibility throughout the supply chain.”
TrakCel is the market leading developer of integrated technologies specifically created in 2012 to manage the international autologous and allogeneic cell, gene and immunotherapy supply chain. TrakCel's software platform has been developed in collaboration with, and increasingly adopted by leading companies in the cell, gene and immunotherapy industries. TrakCel’s solutions deliver real-time control over the entire therapeutic supply chain, from sample collection through manufacturing to treatment delivery. The TrakCel platform accelerates global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while maintaining treatment collection to administration compliance and traceability. TrakCel is headquartered in Cardiff, Wales, UK with US offices in California and New Jersey.
About Ori Biotech
Ori Biotech is a London- and Philadelphia-based CGT manufacturing technology company. Ori has developed a proprietary, flexible manufacturing platform that closes, automates and standardises manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial scale manufacturing. The mission of the Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality and decrease costs in order to enable patient access to this new generation of lifesaving treatments. Founded by Dr Farlan Veraitch and Prof Chris Mason in 2015, the Company has brought together a seasoned Board and executive management team with over 80 years of pharmaceutical, cell therapy and venture building experience including CEO Jason C. Foster (Indivior) and CBO Jason Jones (Miltenyi Biotec) alongside industry-leading expert advisors like Bruce Levine and Anthony Davies. www.oribiotech.com